Morinda citrifolia L.
Species
KNApSAcK Entry
| Organism name | Morinda citrifolia L. |
|---|---|
| Genus | Morinda |
| Family | Rubiaceae |
| Kingdom | Plantae |
NCBI taxonomy
Entry
| Linked NCBI taxonomy name | Morinda citrifolia |
|---|---|
| Linked NCBI taxonomy ID | 43522 |
| Linked level | species |
Family
| Family in NCBI taxonomy | Rubiaceae |
|---|---|
| ID | 24966 |
Kingdom (Superkingdom)
| Kingdom (Superkingdom) in NCBI taxonomy | Viridiplantae |
|---|---|
| ID | 33090 |
Plant class
| Plant class | asterids |
|---|---|
| ID | 71274 |
Natural Activity
List (68)
| Species | Activity |
|---|---|
| Morinda citrifolia L. | Analgesic |
| Morinda citrifolia L. | Analgesic |
| Morinda citrifolia L. | Anthelmintic |
| Morinda citrifolia L. | Antiangiogenic |
| Morinda citrifolia L. | Antiarthritic |
| Morinda citrifolia L. | Antiarthritic |
| Morinda citrifolia L. | Anticancer |
| Morinda citrifolia L. | Anticancer, breast |
| Morinda citrifolia L. | Anticarcinogenic |
| Morinda citrifolia L. | Antifatigue |
| Morinda citrifolia L. | Antihypertensive |
| Morinda citrifolia L. | Antiinflammatory |
| Morinda citrifolia L. | Antioxidant |
| Morinda citrifolia L. | Antiproliferant |
| Morinda citrifolia L. | Antipyretic |
| Morinda citrifolia L. | Antirheumatic |
| Morinda citrifolia L. | Antirheumatic |
| Morinda citrifolia L. | Antisarcomic |
| Morinda citrifolia L. | Antispasmodic |
| Morinda citrifolia L. | Antispasmodic |
| Morinda citrifolia L. | Antitubercular |
| Morinda citrifolia L. | Antitumor |
| Morinda citrifolia L. | Antitumor |
| Morinda citrifolia L. | Antiviral |
| Morinda citrifolia L. | Anxiolytic |
| Morinda citrifolia L. | AP-1-Inhibitor |
| Morinda citrifolia L. | Apoptotic |
| Morinda citrifolia L. | Ascaricide |
| Morinda citrifolia L. | Ascaricide |
| Morinda citrifolia L. | Bactericide |
| Morinda citrifolia L. | Bradycardiac |
| Morinda citrifolia L. | Cathartic |
| Morinda citrifolia L. | Cyclooxygenase Inhibitor |
| Morinda citrifolia L. | Cytotoxic |
| Morinda citrifolia L. | Deobstruent |
| Morinda citrifolia L. | Deobstruent |
| Morinda citrifolia L. | Depurative |
| Morinda citrifolia L. | Depurative |
| Morinda citrifolia L. | Diuretic |
| Morinda citrifolia L. | Diuretic |
| Morinda citrifolia L. | Emetic |
| Morinda citrifolia L. | Emmenagogue |
| Morinda citrifolia L. | Emmenagogue |
| Morinda citrifolia L. | Emollient |
| Morinda citrifolia L. | Emollient |
| Morinda citrifolia L. | Ergogenic |
| Morinda citrifolia L. | Febrifuge |
| Morinda citrifolia L. | Fungicide |
| Morinda citrifolia L. | Fungicide |
| Morinda citrifolia L. | Hepatotoxic |
| Morinda citrifolia L. | Hypotensive |
| Morinda citrifolia L. | Hypotensive |
| Morinda citrifolia L. | Immunomodulator |
| Morinda citrifolia L. | Immunostimulant |
| Morinda citrifolia L. | Laxative |
| Morinda citrifolia L. | Laxative |
| Morinda citrifolia L. | Lipoxygenase Inhibitor |
| Morinda citrifolia L. | Litholytic |
| Morinda citrifolia L. | Litholytic |
| Morinda citrifolia L. | NO-Scavenger |
| Morinda citrifolia L. | Qunone Reductase Inducer |
| Morinda citrifolia L. | Sedative |
| Morinda citrifolia L. | Sedative |
| Morinda citrifolia L. | Stomachic |
| Morinda citrifolia L. | Stomachic |
| Morinda citrifolia L. | Tonic |
| Morinda citrifolia L. | Tonic |
| Morinda citrifolia L. | Vasopresssor |
Metabolite list (16)
| KNApSAcK ID | name | ChEMBL link | CTD link |
# of proteins in
ChEMBL interaction / related OMIM / related KEGG DISEASE |
# of genes in
CTD interaction / related diseases |
KCF-S
cluster |
phytochemical
cluster |
figure |
|---|---|---|---|---|---|---|---|---|
C00029329
|
Roseoside
/ Roseoside A / Roseoside II / (6S,9R)-Roseoside / Vomifoliol beta-D-glucopyranoside |
|
||||||
|
C00003558
|
Ursolic acid
|
CHEMBL297810
CHEMBL56048 CHEMBL300594 CHEMBL169 CHEMBL176234 CHEMBL491715 CHEMBL1316667 CHEMBL1555307 CHEMBL1593360 CHEMBL1979720 |
C005466
|
47 / 26 / 33 | 15 / 12 | No. 13 | No. 51 |
|
|
C00029789
|
Barbinervic acid
|
CHEMBL523209
CHEMBL493908 CHEMBL1271052 |
C052363
|
2 / 0 / 0 | No. 13 | No. 51 |
|
|
|
C00030459
|
Hederagenin
|
CHEMBL486400
CHEMBL492472 CHEMBL1436053 |
C025763
|
7 / 11 / 11 | No. 13 | No. 51 |
|
|
|
C00019064
|
Oleanolic acid
/ Astrantiagenin C / Virgaureagenin B / 3beta-Hydroxyolean-12-en-28-oic acid |
CHEMBL56615
CHEMBL168 CHEMBL180553 CHEMBL365375 CHEMBL486382 CHEMBL1413646 CHEMBL1436454 |
D009828
|
30 / 8 / 12 | 21 / 15 | No. 13 | No. 51 |
|
|
C00031228
|
Rotungenic acid
/ (+)-Rotungenic acid |
CHEMBL523209
CHEMBL493908 CHEMBL1271052 |
2 / 0 / 0 | No. 13 | No. 51 |
|
||
|
C00029993
|
Clethric acid
|
No. 13 | No. 51 |
|
||||
|
C00029548
|
5,15-Dimethylmorindol
|
CHEMBL445667
|
No. 41 | No. 62 |
|
|||
|
C00029978
|
Citrifoside
/ (-)-Citrifoside |
No. 56 | No. 36 |
|
||||
|
C00030092
|
Deacetylasperuloside
/ Deacetyl asperuloside |
CHEMBL462113
|
No. 100 | No. 36 |
|
|||
|
C00029507
|
Pomolic acid acetate
/ 3-O-Acetylpomolic acid |
No. 177 |
|
|||||
|
C00002494
|
Pteryxin
|
CHEMBL71876
CHEMBL1376728 CHEMBL1494966 CHEMBL1884860 |
C019546
|
16 / 18 / 45 | No. 224 | No. 25 |
|
|
|
C00019999
|
Peucedanocoumarin III
|
CHEMBL71876
CHEMBL1376728 CHEMBL1494966 CHEMBL1884860 |
16 / 18 / 45 | No. 224 | No. 25 |
|
||
|
C00003467
|
Phytol
/ trans-Phytol |
CHEMBL390773
CHEMBL1644111 |
D010836
|
0 / 5 | No. 641 | No. 38 |
|
|
|
C00029390
|
Phaeophorbide-a-methyl ester
/ Pheophorbide a' methyl ester / 13-epi-Phaeophorbide a methyl ester |
CHEMBL408290
CHEMBL504821 CHEMBL1985396 |
No. 990 |
|
||||
|
C00000332
|
Methyl pheophorbide a
|
CHEMBL408290
CHEMBL504821 CHEMBL1985396 |
C032625
|
No. 990 |
|
Human Protein / Gene in interactions
69 ChEMBL Protein in interactions
| accession | description | class description | KNApSAcK metabolite in interactions |
# of diseases
(OMIM / KEGG) |
|---|---|---|---|---|
| P18031 | Tyrosine-protein phosphatase non-receptor type 1 | Tyr | C00003558 C00019064 C00029789 C00030459 C00031228 | 0 / 0 |
| P08684 | Cytochrome P450 3A4 | Cytochrome P450 3A4 | C00002494 C00003558 C00019999 C00030459 | 0 / 1 |
| Q9UNA4 | DNA polymerase iota | Enzyme | C00002494 C00019064 C00019999 | 0 / 0 |
| O94782 | Ubiquitin carboxyl-terminal hydrolase 1 | Enzyme | C00002494 C00003558 C00019999 | 0 / 0 |
| O75496 | Geminin | Unclassified protein | C00002494 C00019064 C00019999 | 0 / 0 |
| P15559 | NAD(P)H dehydrogenase [quinone] 1 | Enzyme | C00029789 C00030459 C00031228 | 0 / 0 |
| O75604 | Ubiquitin carboxyl-terminal hydrolase 2 | Enzyme | C00003558 C00019064 C00030459 | 0 / 0 |
| Q9NR56 | Muscleblind-like protein 1 | Unclassified protein | C00002494 C00019999 | 1 / 0 |
| Q01196 | Runt-related transcription factor 1 | Unclassified protein | C00003558 C00019064 | 1 / 4 |
| Q13951 | Core-binding factor subunit beta | Unclassified protein | C00003558 C00019064 | 0 / 1 |
| P24666 | Low molecular weight phosphotyrosine protein phosphatase | Tyr | C00003558 C00019064 | 0 / 0 |
| Q8TDU6 | G-protein coupled bile acid receptor 1 | Steroid-like ligand receptor | C00003558 C00019064 | 0 / 0 |
| P06746 | DNA polymerase beta | Enzyme | C00003558 C00019064 | 0 / 0 |
| P02545 | Prelamin-A/C | Unclassified protein | C00003558 C00030459 | 11 / 10 |
| P08047 | Transcription factor Sp1 | Unclassified protein | C00003558 C00030459 | 0 / 0 |
| B2RXH2 | Lysine-specific demethylase 4E | Enzyme | C00002494 C00019999 | 0 / 0 |
| P23469 | Receptor-type tyrosine-protein phosphatase epsilon | Receptor tyrosine-protein phosphatase | C00003558 C00019064 | 0 / 0 |
| P10586 | Receptor-type tyrosine-protein phosphatase F | Receptor tyrosine-protein phosphatase | C00003558 C00019064 | 0 / 0 |
| P29350 | Tyrosine-protein phosphatase non-receptor type 6 | Tyr | C00003558 C00019064 | 0 / 0 |
| P35354 | Prostaglandin G/H synthase 2 | Oxidoreductase | C00003558 C00019064 | 0 / 3 |
| P10253 | Lysosomal alpha-glucosidase | Hydrolase | C00002494 C00019999 | 1 / 1 |
| P23219 | Prostaglandin G/H synthase 1 | Oxidoreductase | C00003558 C00019064 | 0 / 0 |
| P00352 | Retinal dehydrogenase 1 | Enzyme | C00002494 C00019999 | 0 / 0 |
| P17706 | Tyrosine-protein phosphatase non-receptor type 2 | Tyr | C00003558 C00019064 | 0 / 1 |
| Q16236 | Nuclear factor erythroid 2-related factor 2 | Unclassified protein | C00002494 C00019999 | 0 / 0 |
| Q92830 | Histone acetyltransferase KAT2A | Enzyme | C00003558 C00019064 | 0 / 0 |
| P84022 | Mothers against decapentaplegic homolog 3 | Unclassified protein | C00002494 C00019999 | 2 / 0 |
| O60218 | Aldo-keto reductase family 1 member B10 | Enzyme | C00003558 C00019064 | 0 / 0 |
| P15121 | Aldose reductase | Enzyme | C00003558 C00019064 | 0 / 0 |
| P49841 | Glycogen synthase kinase-3 beta | Gsk | C00003558 C00019064 | 0 / 0 |
| P43220 | Glucagon-like peptide 1 receptor | Glucagon-like peptide receptor | C00002494 C00019999 | 0 / 0 |
| Q99700 | Ataxin-2 | Unclassified protein | C00002494 C00019999 | 1 / 1 |
| P83916 | Chromobox protein homolog 1 | Unclassified protein | C00003558 C00019064 | 0 / 0 |
| P04637 | Cellular tumor antigen p53 | Transcription Factor | C00002494 C00019999 | 7 / 37 |
| P11511 | Cytochrome P450 19A1 | Cytochrome P450 19A1 | C00003558 C00019064 | 2 / 2 |
| P06280 | Alpha-galactosidase A | Enzyme | C00002494 C00019999 | 1 / 1 |
| Q96RI1 | Bile acid receptor | NR1H4 | C00003558 C00019064 | 0 / 0 |
| P27695 | DNA-(apurinic or apyrimidinic site) lyase | Enzyme | C00003558 C00019064 | 0 / 0 |
| P18433 | Receptor-type tyrosine-protein phosphatase alpha | Receptor tyrosine-protein phosphatase | C00003558 C00019064 | 0 / 0 |
| P15428 | 15-hydroxyprostaglandin dehydrogenase [NAD(+)] | Enzyme | C00002494 C00019999 | 2 / 2 |
| Q99714 | 3-hydroxyacyl-CoA dehydrogenase type-2 | Enzyme | C00002494 C00019999 | 3 / 3 |
| P10635 | Cytochrome P450 2D6 | Cytochrome P450 2D6 | C00003558 | 1 / 0 |
| P35236 | Tyrosine-protein phosphatase non-receptor type 7 | Tyr | C00019064 | 0 / 0 |
| Q96QE3 | ATPase family AAA domain-containing protein 5 | Unclassified protein | C00019064 | 0 / 0 |
| P56524 | Histone deacetylase 4 | Hydrolase | C00003558 | 1 / 1 |
| P19838 | Nuclear factor NF-kappa-B p105 subunit | Transcription Factor | C00003558 | 0 / 0 |
| P30305 | M-phase inducer phosphatase 2 | Ser_Thr_Tyr | C00003558 | 0 / 0 |
| P35228 | Nitric oxide synthase, inducible | Enzyme | C00019064 | 1 / 1 |
| P33261 | Cytochrome P450 2C19 | Cytochrome P450 2C19 | C00003558 | 1 / 1 |
| O15379 | Histone deacetylase 3 | Hydrolase | C00003558 | 0 / 0 |
| Q04206 | Transcription factor p65 | Transcription Factor | C00003558 | 0 / 0 |
| P05177 | Cytochrome P450 1A2 | Cytochrome P450 1A2 | C00003558 | 0 / 0 |
| Q9UQL6 | Histone deacetylase 5 | Hydrolase | C00003558 | 0 / 0 |
| Q07869 | Peroxisome proliferator-activated receptor alpha | NR1C1 | C00003558 | 0 / 0 |
| P28845 | Corticosteroid 11-beta-dehydrogenase isozyme 1 | Enzyme | C00003558 | 1 / 1 |
| Q9UBN7 | Histone deacetylase 6 | Hydrolase | C00003558 | 0 / 0 |
| P11712 | Cytochrome P450 2C9 | Cytochrome P450 2C9 | C00003558 | 0 / 1 |
| P04054 | Phospholipase A2 | Enzyme | C00019064 | 0 / 0 |
| P80365 | Corticosteroid 11-beta-dehydrogenase isozyme 2 | Enzyme | C00003558 | 1 / 1 |
| P51452 | Dual specificity protein phosphatase 3 | Ser_Thr_Tyr | C00019064 | 0 / 0 |
| Q9UBT6 | DNA polymerase kappa | Enzyme | C00030459 | 0 / 0 |
| P10828 | Thyroid hormone receptor beta | NR1A2 | C00003558 | 3 / 1 |
| P46063 | ATP-dependent DNA helicase Q1 | Enzyme | C00003558 | 0 / 0 |
| O75874 | Isocitrate dehydrogenase [NADP] cytoplasmic | Enzyme | C00003558 | 1 / 0 |
| O00255 | Menin | Unclassified protein | C00003558 | 2 / 5 |
| Q03164 | Histone-lysine N-methyltransferase 2A | Enzyme | C00003558 | 1 / 2 |
| Q13547 | Histone deacetylase 1 | Hydrolase | C00003558 | 0 / 0 |
| Q06124 | Tyrosine-protein phosphatase non-receptor type 11 | Tyr | C00019064 | 4 / 2 |
| O94925 | Glutaminase kidney isoform, mitochondrial | Enzyme | C00003558 | 0 / 0 |
31 Gene in CTD interactions
| gene | gene name | gene description | KNApSAcK metabolite in interactions |
|---|---|---|---|
| 836 | CASP3, CPP32, CPP32B, SCA-1 | caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) |
C00003558
C00019064
|
| 7153 | TOP2A, TOP2, TP2A | topoisomerase (DNA) II alpha 170kDa (EC:5.99.1.3) |
C00003558
C00019064
|
| 7150 | TOP1, TOPI | topoisomerase (DNA) I (EC:5.99.1.2) |
C00003558
C00019064
|
| 3383 | ICAM1, BB2, CD54, P3.58 | intercellular adhesion molecule 1 |
C00003558
C00019064
|
| 841 | CASP8, ALPS2B, CAP4, Casp-8, FLICE, MACH, MCH5 | caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) |
C00003558
C00019064
|
| 177 | AGER, RAGE | advanced glycosylation end product-specific receptor |
C00019064
|
| 54205 | CYCS, CYC, HCS, THC4 | cytochrome c, somatic |
C00003558
|
| 1557 | CYP2C19, CPCJ, CYP2C, P450C2C, P450IIC19 | cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
C00003558
|
| 596 | BCL2, Bcl-2, PPP1R50 | B-cell CLL/lymphoma 2 |
C00003558
|
| 4313 | MMP2, CLG4, CLG4A, MMP-II, MONA, TBE-1 | matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase) (EC:3.4.24.24) |
C00003558
|
| 4318 | MMP9, CLG4B, GELB, MANDP2, MMP-9 | matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) (EC:3.4.24.35) |
C00003558
|
| 142 | PARP1, ADPRT, ADPRT_1, ADPRT1, ARTD1, PARP, PARP-1, PPOL, pADPRT-1 | poly (ADP-ribose) polymerase 1 (EC:2.4.2.30) |
C00003558
|
| 7040 | TGFB1, CED, DPD1, LAP, TGFB, TGFbeta | transforming growth factor, beta 1 |
C00003558
|
| 581 | BAX, BCL2L4 | BCL2-associated X protein |
C00003558
|
| 578 | BAK1, BAK, BAK-LIKE, BCL2L7, CDN1 | BCL2-antagonist/killer 1 |
C00003558
|
| 9131 | AIFM1, AIF, CMTX4, COWCK, COXPD6, PDCD8 | apoptosis-inducing factor, mitochondrion-associated, 1 |
C00003558
|
| 847 | CAT | catalase (EC:1.11.1.6) |
C00019064
|
| 595 | CCND1, BCL1, D11S287E, PRAD1, U21B31 | cyclin D1 |
C00019064
|
| 1544 | CYP1A2, CP12, P3-450, P450(PA) | cytochrome P450, family 1, subfamily A, polypeptide 2 (EC:1.14.14.1) |
C00019064
|
| 1576 | CYP3A4, CP33, CP34, CYP3A, CYP3A3, CYPIIIA3, CYPIIIA4, HLP, NF-25, P450C3, P450PCN1 | cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) |
C00019064
|
| 3065 | HDAC1, GON-10, HD1, RPD3, RPD3L1 | histone deacetylase 1 (EC:3.5.1.98) |
C00019064
|
| 3146 | HMGB1, HMG1, HMG3, SBP-1 | high mobility group box 1 |
C00019064
|
| 5594 | MAPK1, ERK, ERK2, ERT1, MAPK2, P42MAPK, PRKM1, PRKM2, p38, p40, p41, p41mapk | mitogen-activated protein kinase 1 (EC:2.7.11.24) |
C00019064
|
| 5595 | MAPK3, ERK-1, ERK1, ERT2, HS44KDAP, HUMKER1A, P44ERK1, P44MAPK, PRKM3, p44-ERK1, p44-MAPK | mitogen-activated protein kinase 3 (EC:2.7.11.24) |
C00019064
|
| 4233 | MET, AUTS9, HGFR, RCCP2, c-Met | met proto-oncogene (EC:2.7.10.1) |
C00019064
|
| 4780 | NFE2L2, NRF2 | nuclear factor, erythroid 2-like 2 |
C00019064
|
| 5052 | PRDX1, MSP23, NKEF-A, NKEFA, PAG, PAGA, PAGB, PRX1, PRXI, TDPX2 | peroxiredoxin 1 (EC:1.11.1.15) |
C00019064
|
| 5728 | PTEN, 10q23del, BZS, CWS1, DEC, GLM2, MHAM, MMAC1, PTEN1, TEP1 | phosphatase and tensin homolog (EC:3.1.3.67 3.1.3.16 3.1.3.48) |
C00019064
|
| 6401 | SELE, CD62E, ELAM, ELAM1, ESEL, LECAM2 | selectin E |
C00019064
|
| 7124 | TNF, DIF, TNF-alpha, TNFA, TNFSF2 | tumor necrosis factor |
C00019064
|
| 7412 | VCAM1, CD106, INCAM-100 | vascular cell adhesion molecule 1 |
C00019064
|
Related Diseases
Diseases related to proteins in ChEMBL interactions
OMIM (49)
| OMIM | preferred title | UniProt |
|---|---|---|
| #300438 | 17-beta-hydroxysteroid dehydrogenase x deficiency |
Q99714
|
| #202300 | Adrenocortical carcinoma, hereditary; adcc |
P04637
|
| #218030 | Apparent mineralocorticoid excess; ame |
P80365
|
| #613546 | Aromatase deficiency |
P11511
|
| #139300 | Aromatase excess syndrome; aexs |
P11511
|
| #614740 | Basal cell carcinoma, susceptibility to, 7; bcc7 |
P04637
|
| #600430 | Brachydactyly-mental retardation syndrome; bdmr |
P56524
|
| #115200 | Cardiomyopathy, dilated, 1a; cmd1a |
P02545
|
| #212112 | Cardiomyopathy, dilated, with hypergonadotropic hypogonadism |
P02545
|
| #605588 | Charcot-marie-tooth disease, axonal, type 2b1; cmt2b1 |
P02545
|
| #114500 | Colorectal cancer; crc |
P84022
|
| #604931 | Cortisone reductase deficiency 1; cortrd1 |
P28845
|
| #119900 | Digital clubbing, isolated congenital |
P15428
|
| #609535 | Drug metabolism, poor, cyp2c19-related |
P33261
|
| #608902 | Drug metabolism, poor, cyp2d6-related |
P10635
|
| #181350 | Emery-dreifuss muscular dystrophy 2, autosomal dominant; edmd2 |
P02545
|
| #133239 | Esophageal cancer |
P04637
|
| #301500 | Fabry disease |
P06280
|
| #137800 | Glioma susceptibility 1; glm1 |
O75874
|
| #232300 | Glycogen storage disease ii |
P10253
|
| #605130 | Hairy elbows, short stature, facial dysmorphism, and developmental delay |
Q03164
|
| #610140 | Heart-hand syndrome, slovenian type |
P02545
|
| #176670 | Hutchinson-gilford progeria syndrome; hgps |
P02545
|
| #145000 | Hyperparathyroidism 1; hrpt1 |
O00255
|
| #259100 | Hypertrophic osteoarthropathy, primary, autosomal recessive, 1; phoar1 |
P15428
|
| #607785 | Juvenile myelomonocytic leukemia; jmml |
Q06124
|
| #151100 | Leopard syndrome 1 |
Q06124
|
| #151623 | Li-fraumeni syndrome 1; lfs1 |
P04637
|
| #151660 | Lipodystrophy, familial partial, type 2; fpld2 |
P02545
|
| #613795 | Loeys-dietz syndrome, type 3; lds3 |
P84022
|
| #211980 | Lung cancer |
P04637
|
| #611162 | Malaria, susceptibility to |
P35228
|
| #248370 | Mandibuloacral dysplasia with type a lipodystrophy; mada |
P02545
|
| #300705 | Mental retardation, x-linked 17; mrx17 |
Q99714
|
| #300220 | Mental retardation, x-linked, syndromic 10; mrxs10 |
Q99714
|
| #156250 | Metachondromatosis; metcds |
Q06124
|
| #131100 | Multiple endocrine neoplasia, type i; men1 |
O00255
|
| #613205 | Muscular dystrophy, congenital, lmna-related |
P02545
|
| #159001 | Muscular dystrophy, limb-girdle, type 1b; lgmd1b |
P02545
|
| #160900 | Myotonic dystrophy 1; dm1 |
Q9NR56
|
| #163950 | Noonan syndrome 1; ns1 |
Q06124
|
| #260500 | Papilloma of choroid plexus; cpp |
P04637
|
| #601399 | Platelet disorder, familial, with associated myeloid malignancy |
Q01196
|
| #275210 | Restrictive dermopathy, lethal |
P02545
|
| #183090 | Spinocerebellar ataxia 2; sca2 |
Q99700
|
| #275355 | Squamous cell carcinoma, head and neck; hnscc |
P04637
|
| #188570 | Thyroid hormone resistance, generalized, autosomal dominant; grth |
P10828
|
| #274300 | Thyroid hormone resistance, generalized, autosomal recessive; grth |
P10828
|
| #145650 | Thyroid hormone resistance, selective pituitary; prth |
P10828
|
KEGG DISEASE (74)
| KEGG | name | UniProt |
|---|---|---|
| H00033 | Adrenal carcinoma |
O00255
(related)
P04637 (related) |
| H00034 | Carcinoid |
O00255
(related)
|
| H00045 | Malignant islet cell carcinoma |
O00255
(related)
|
| H00246 | Primary hyperparathyroidism |
O00255
(related)
|
| H01102 | Pituitary adenomas |
O00255
(related)
|
| H00264 | Charcot-Marie-Tooth disease (CMT) |
P02545
(related)
|
| H00294 | Dilated cardiomyopathy (DCM) |
P02545
(related)
|
| H00420 | Familial partial lipodystrophy (FPL) |
P02545
(related)
|
| H00563 | Emery-Dreifuss muscular dystrophy |
P02545
(related)
|
| H00590 | Congenital muscular dystrophies (CMD/MDC) |
P02545
(related)
|
| H00593 | Limb-girdle muscular dystrophy (LGMD) |
P02545
(related)
|
| H00601 | Hutchinson-Gilford progeria syndrome |
P02545
(related)
|
| H00663 | Restrictive dermopathy |
P02545
(related)
|
| H00665 | Mandibuloacral dysplasia |
P02545
(related)
|
| H01216 | Left ventricular noncompaction (LVNC) |
P02545
(related)
|
| H00004 | Chronic myeloid leukemia (CML) |
P04637
(related)
Q01196 (related) |
| H00005 | Chronic lymphocytic leukemia (CLL) |
P04637
(related)
|
| H00006 | Hairy-cell leukemia |
P04637
(related)
|
| H00008 | Burkitt lymphoma |
P04637
(related)
|
| H00009 | Adult T-cell leukemia |
P04637
(related)
|
| H00010 | Multiple myeloma |
P04637
(related)
|
| H00013 | Small cell lung cancer |
P04637
(related)
|
| H00014 | Non-small cell lung cancer |
P04637
(related)
|
| H00015 | Malignant pleural mesothelioma |
P04637
(related)
|
| H00016 | Oral cancer |
P04637
(related)
P04637 (marker) |
| H00017 | Esophageal cancer |
P04637
(related)
P04637 (marker) P35228 (related) P35354 (related) |
| H00018 | Gastric cancer |
P04637
(related)
|
| H00019 | Pancreatic cancer |
P04637
(related)
P04637 (marker) |
| H00020 | Colorectal cancer |
P04637
(related)
P04637 (marker) |
| H00022 | Bladder cancer |
P04637
(related)
|
| H00025 | Penile cancer |
P04637
(related)
P04637 (marker) P35354 (related) |
| H00026 | Endometrial Cancer |
P04637
(related)
|
| H00027 | Ovarian cancer |
P04637
(related)
|
| H00028 | Choriocarcinoma |
P04637
(related)
|
| H00029 | Vulvar cancer |
P04637
(related)
|
| H00031 | Breast cancer |
P04637
(related)
|
| H00032 | Thyroid cancer |
P04637
(related)
|
| H00036 | Osteosarcoma |
P04637
(related)
P08684 (marker) |
| H00038 | Malignant melanoma |
P04637
(related)
|
| H00039 | Basal cell carcinoma |
P04637
(related)
|
| H00040 | Squamous cell carcinoma |
P04637
(related)
|
| H00041 | Kaposi's sarcoma |
P04637
(related)
|
| H00042 | Glioma |
P04637
(related)
P04637 (marker) |
| H00044 | Cancer of the anal canal |
P04637
(related)
|
| H00046 | Cholangiocarcinoma |
P04637
(related)
P35354 (related) |
| H00047 | Gallbladder cancer |
P04637
(related)
|
| H00048 | Hepatocellular carcinoma |
P04637
(related)
|
| H00055 | Laryngeal cancer |
P04637
(related)
P04637 (marker) |
| H00881 | Li-Fraumeni syndrome |
P04637
(related)
|
| H01007 | Choroid plexus papilloma |
P04637
(related)
|
| H00021 | Renal cell carcinoma |
P04637
(marker)
|
| H00125 | Fabry disease |
P06280
(related)
|
| H00069 | Glycogen storage diseases (GSD) |
P10253
(related)
|
| H00249 | Thyroid hormone resistance syndrome |
P10828
(related)
|
| H00599 | 46,XX disorders of sex development (Disorders related to androgen excess) |
P11511
(related)
|
| H00794 | Aromatase excess syndrome |
P11511
(related)
|
| H01205 | Coumarin resistance |
P11712
(related)
|
| H00457 | Primary hypertrophic osteoarthropathy (PHO) |
P15428
(related)
|
| H01246 | Isolated congenital nail clubbing (ICNC) |
P15428
(related)
|
| H00408 | Type I diabetes mellitus |
P17706
(related)
|
| H01111 | Cortisone reductase deficiency (CRD) |
P28845
(related)
|
| H01171 | Poor drug metabolism (PM) |
P33261
(related)
|
| H00561 | Brachydacytly-mental retardation syndrome and Smith-Magenis syndrome |
P56524
(related)
|
| H00259 | Apparent mineralocorticoid excess syndrome |
P80365
(related)
|
| H00001 | Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia) |
Q01196
(related)
Q01196 (marker) Q03164 (related) Q03164 (marker) |
| H00003 | Acute myeloid leukemia (AML) |
Q01196
(related)
Q01196 (marker) Q13951 (marker) |
| H00978 | Thrombocytopenia (THC) |
Q01196
(related)
|
| H00002 | Acute lymphoblastic leukemia (ALL) (precursor T lymphoblastic leukemia) |
Q03164
(related)
|
| H00523 | Noonan syndrome and related disorders |
Q06124
(related)
|
| H01018 | Metachondromatosis |
Q06124
(related)
|
| H00063 | Spinocerebellar ataxia (SCA) |
Q99700
(related)
|
| H00480 | Non-syndromic X-linked mental retardation |
Q99714
(related)
|
| H00658 | Syndromic X-linked mental retardation |
Q99714
(related)
|
| H00925 | 2-Methyl-3-hydroxybutyryl-CoA dehydrogenase (MHBD) deficiency |
Q99714
(related)
|
Diseases related to CTD interactions
25 disease in interactions with metabolites
| MESH or OMIM | name |
KNApSAcK
metabolite |
|---|---|---|
| D006949 | Hyperlipidemias |
C00003558
C00019064 |
| D056486 | Drug-Induced Liver Injury |
C00019064
C00003467 |
| D009369 | Neoplasms |
C00003558
C00019064 |
| D017202 | Myocardial Ischemia |
C00003558
C00019064 |
| D008103 | Liver Cirrhosis |
C00003558
C00019064 |
| D007249 | Inflammation |
C00003558
C00019064 |
| D006965 | Hyperplasia |
C00003558
C00003467 |
| D002252 | Carbon Tetrachloride Poisoning |
C00019064
|
| D006943 | Hyperglycemia |
C00003558
|
| D003921 | Diabetes Mellitus, Experimental |
C00003558
|
| D002471 | Cell Transformation, Neoplastic |
C00003558
|
| D012878 | Skin Neoplasms |
C00003558
|
| D001284 | Atrophy |
C00003558
|
| D006528 | Carcinoma, Hepatocellular |
C00003558
|
| D050171 | Dyslipidemias |
C00019064
|
| D018149 | Glucose Intolerance |
C00019064
|
| D007674 | Kidney Diseases |
C00019064
|
| D008106 | Liver Cirrhosis, Experimental |
C00019064
|
| D008107 | Liver Diseases |
C00019064
|
| D009765 | Obesity |
C00019064
|
| D011041 | Poisoning |
C00019064
|
| D011230 | Precancerous Conditions |
C00019064
|
| D006984 | Hypertrophy |
C00003467
|
| D009336 | Necrosis |
C00003467
|
| D015431 | Weight Loss |
C00003467
|